Welcome to our dedicated page for Ascendis Pharma SEC filings (Ticker: ASND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ascendis Pharma A/S (ASND) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. Ascendis files annual reports on Form 20-F and furnishes interim updates on Form 6-K, which include clinical, regulatory, financial, and corporate information related to its TransCon-based therapies.
In these filings, investors can review details on Ascendis’ pharmaceutical preparation manufacturing activities, including revenue from commercial products such as YORVIPATH (TransCon PTH) for adults with hypoparathyroidism and SKYTROFA (TransCon hGH) for growth hormone deficiency. Unaudited condensed consolidated interim financial statements, management’s discussion and analysis, and segment information by geography (North America, Europe, and rest of world) are typically included in quarterly 6-K submissions.
Filings also describe the status of key pipeline programs like TransCon CNP for children with achondroplasia, combination therapy with TransCon CNP and TransCon hGH in the COACH trial, and TransCon IL-2 β/γ in oncology, along with updates on regulatory reviews by the U.S. Food and Drug Administration and the European Medicines Agency. Additional 6-Ks may cover warrant grants, share capital changes, and the operation of equity compensation plans and share repurchase programs.
Stock Titan enhances these documents with AI-powered summaries that highlight the main points of lengthy 20-F and 6-K filings, helping users quickly understand revenue drivers, operating results, and key clinical or regulatory events. Real-time updates from EDGAR ensure that new Ascendis filings, including financial statements and other material disclosures, are available promptly, while structured access makes it easier to locate specific reports relevant to ASND analysis.
Ascendis Pharma A/S intends to sell 10,000 American Depositary Shares (ADS) by 03/05/2026. The filing lists the sale method as a warrant exercise for $2,400,000.00 and indicates trading on Nasdaq. The transaction type is listed as cash.
Ascendis Pharma A/S proposes sale of 94,000 American Depository Shares. The filing lists a warrant exercise by the issuer for 94,000 ADS on 03/05/2026 with cash consideration. The filing also records prior sales of 86,860 ADS by Jan Moller Mikkelsen on 01/13/2026.